Condition: Diffuse Large B-cell Lymphoma (DLBCL) · Sponsor: Xynomic Pharmaceuticals, Inc.
An open-label, single-arm, multi-center phase 2 study to evaluate the efficacy and safety of abexinostat, as monotherapy in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
This description comes directly from the study's public registry record.
Bing Zhao, MD · (01186)13716386801 · bing.zhao@xynomicpharma.com
Sophia Paspal, PhD RAC · 610-405-5974 · sophia.paspal@xynomicpharma.com
Always discuss trial participation with your own doctor first.
| Cancer Hospital Chinese Academy of Medical Sciences | Beijing, China | Recruiting |
| China-Japan Friendship Hospital | Beijing, China | Recruiting |
| Peking University Third Hospital | Beijing, China | Recruiting |
| West China Hospital, Sichuan University | Chengdu, China | Recruiting |
| The First Affiliate Hospital of Dalian Medical University | Dalian, China | Recruiting |
| Fujian Medical University Union Hospital | Fuzhou, China | Recruiting |
| Fujian Provincial Cancer Hospital | Fuzhou, China | Recruiting |
| Cancer Center of Guangzhou Medical University | Guangzhou, China | Recruiting |
| Sun Yai-Sen Memorial Hospital, Sun Yai-Sen University | Guangzhou, China | Recruiting |
| Zhejiang Cancer Hospital | Hangzhou, China | Recruiting |
| The Affiliated Tumor Hospital of Harbin Medical University | Harbin, China | Recruiting |
| The First Hospital of Lanzhou University | Lanzhou, China | Recruiting |
+ 11 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03936153